Related references
Note: Only part of the references are listed.Risk Stratification in Autoimmune Cholestatic Liver Diseases: Opportunities for Clinicians and Trialists
Palak J. Trivedi et al.
HEPATOLOGY (2016)
Engineered Fibroblast Growth Factor 19 Reduces Liver Injury and Resolves Sclerosing Cholangitis in Mdr2-Deficient Mice
Mei Zhou et al.
HEPATOLOGY (2016)
Chronic Expression of Interferon-Gamma Leads to Murine Autoimmune Cholangitis With a Female Predominance
Heekyong R. Bae et al.
HEPATOLOGY (2016)
Soluble Adenylyl Cyclase Regulates Bile Salt-Induced Apoptosis in Human Cholangiocytes
Jung-Chin Chang et al.
HEPATOLOGY (2016)
Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis
Satomi Hisamoto et al.
JOURNAL OF AUTOIMMUNITY (2016)
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
F. Nevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways
Heather J. Cordell et al.
NATURE COMMUNICATIONS (2015)
A nontumorigenic variant of FGF19 treats cholestatic liver diseases
Jian Luo et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis
Gideon M. Hirschfield et al.
Annual Review of Pathology-Mechanisms of Disease (2013)
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver
Ye Htun Oo et al.
JOURNAL OF HEPATOLOGY (2012)
Share Paper
